Loading patent…
AssigneeCentro de Ingenieria Genetica y Biotecnologia
InventorsMaribel Guerra Vallespi, Manuel de Jesus Arana Rosainz
Estimating the term…
The present invention relates a novel immunological effect of one peptide from Limulus anti-LPS factor protein. The immunological effect are, (1) induce an antiviral state in both the Hep-2 and MDBK cell lines, (2) Supernatant from human mononuclear cells stimulated with peptide Limulus anti-LPS factor (LALF) is able to induce antiviral effect on Hep-2 cell line by mean of IFN-γ (3) LALF peptide is able to modulate the immune response in vitro and in vivo. The present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune responses, without stimulating the production of certain biochemical mediators (e.g., TNF-α,) that can cause detrimental effects, such as fever and inflammation.
A method for the prophylaxis or treatment of viral infections or diseases of viral origin, comprising administering a pharmaceutical formulation containing a peptide or protein with a chain backbone having the amino acids from position 31 to 52 of Limulus polyphemus anti-LPS factor (LALF) (SEQ ID NO:
Dependencies are inferred from the claim text.